Erica L. Schwalm
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Erica L. Schwalm has a total of 196 co-authors. Here are the top co-authors by number of shared publications:
- Jeffrey T. Kuethe
Process Research and Development, Merck & Co., Inc., Rahway, NJ, USA
4 shared publications - Alexandra C. Sun
Process Research and Development, Merck & Co., Inc., Rahway, NJ, USA
3 shared publications - Anna Fryszkowska
Merck & Co., Inc
3 shared publications - Eric Sirota
Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
3 shared publications - Kai-Jiong Xiao
Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
3 shared publications - Sandra A. Robaire
Global Science, Engineering, and Commercialization, Merck & Co., Inc., Rahway, NJ, USA
3 shared publications
Latest Publications
- 31 August 2026
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 30 (9) , 2540-2548
Synthesis of N -Linked Amino-Hexyl Fluorotryptophan for Enlicitide, Part 2: Process Improvements toward Commercial Manufacture
Herein, we report the development of a robust manufacturing process for N-linked amino-hexyl fluorotryptophan 3, a key building block for enlicitide decanoate (MK-0616), which is an orally bioavailable inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9). Targeted process development enabled safe operation of the Delépine reaction, increased yields for the hexamine hydrolysis and enzymatic tryptophan synthesis, and established a robust and selective N-alkylation of 5-fluorotryptophan. Collectively, these improvements afforded the target product with high yield, >98.5% purity, and favorable physical properties suitable for commercial manufacture.
- 31 August 2026
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 30 (9) , 2540-2548
Synthesis of N -Linked Amino-Hexyl Fluorotryptophan for Enlicitide, Part 2: Process Improvements toward Commercial Manufacture
Herein, we report the development of a robust manufacturing process for N-linked amino-hexyl fluorotryptophan 3, a key building block for enlicitide decanoate (MK-0616), which is an orally bioavailable inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9). Targeted process development enabled safe operation of the Delépine reaction, increased yields for the hexamine hydrolysis and enzymatic tryptophan synthesis, and established a robust and selective N-alkylation of 5-fluorotryptophan. Collectively, these improvements afforded the target product with high yield, >98.5% purity, and favorable physical properties suitable for commercial manufacture.
- Top Cited Papers
- 7 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 392 (6798) , 643-647
Biocatalytic cascades enable manufacture of the macrocyclic peptide enlicitide
Historically, many compelling therapeutic targets have been accessible only by injectable biologic drugs. Macrocyclic peptides, such as the proprotein convertase subtilisin/kexin type 9 inhibitor enlicitide for the treatment of atherosclerotic cardiovascular disease, are beginning to unlock these targets to orally administered therapies to enable broader patient access. We report the convergent biocatalytic assembly of enlicitide from simple building blocks enabled by a suite of engineered enzymes to catalyze selective peptide fragment formation, coupling, and macrocyclization in a protecting group–free manner. Together with efficient crystallizations that obviate the need for chromatography, this approach reduces the number of steps by greater than half compared with prior state-of-the-art methods, addressing long-standing synthetic challenges and offering a sustainable blueprint for the scalable development of complex peptide therapeutics.
- 7 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 392 (6798) , 643-647
Top Cited PapersBiocatalytic cascades enable manufacture of the macrocyclic peptide enlicitide
Historically, many compelling therapeutic targets have been accessible only by injectable biologic drugs. Macrocyclic peptides, such as the proprotein convertase subtilisin/kexin type 9 inhibitor enlicitide for the treatment of atherosclerotic cardiovascular disease, are beginning to unlock these targets to orally administered therapies to enable broader patient access. We report the convergent biocatalytic assembly of enlicitide from simple building blocks enabled by a suite of engineered enzymes to catalyze selective peptide fragment formation, coupling, and macrocyclization in a protecting group–free manner. Together with efficient crystallizations that obviate the need for chromatography, this approach reduces the number of steps by greater than half compared with prior state-of-the-art methods, addressing long-standing synthetic challenges and offering a sustainable blueprint for the scalable development of complex peptide therapeutics.
- Open Access
Structural Basis for C 8 methylation of 23S ribosomal RNA by Cfr
Cfr methylates C 8 of adenosine 2503 (A2503) in 23 S ribosomal RNA (rRNA) and will also methylate C 2 of A2503 after methylating C 8 . C 8 methylation confers resistance to more than five classes of clinically used antibiotics, highlighting it as a worrisome mechanism of antibiotic resistance. Here, we report the structure of Cfr, determined by cryogenic electron microscopy (Cryo-EM). Despite its small size (∼36 kDa), we exploit a transient protein–RNA crosslink that forms during catalysis, which requires Cys105 to resolve. Using a Cfr Cys105Ala variant and an 87-nucleotide strand of rRNA, we isolate the crosslinked species and determine its structure to 3.0 Å resolution. Notably, the 87-mer rRNA adopts an L-shaped conformation characteristic of tRNAs, rather than the conformation it assumes in the ribosome. One Sentence Summary: Cryo-EM structure of Cfr, a radical S-adenosylmethionine methylase that confers antibiotic resistance
Open AccessStructural Basis for C 8 methylation of 23S ribosomal RNA by Cfr
Cfr methylates C 8 of adenosine 2503 (A2503) in 23 S ribosomal RNA (rRNA) and will also methylate C 2 of A2503 after methylating C 8 . C 8 methylation confers resistance to more than five classes of clinically used antibiotics, highlighting it as a worrisome mechanism of antibiotic resistance. Here, we report the structure of Cfr, determined by cryogenic electron microscopy (Cryo-EM). Despite its small size (∼36 kDa), we exploit a transient protein–RNA crosslink that forms during catalysis, which requires Cys105 to resolve. Using a Cfr Cys105Ala variant and an 87-nucleotide strand of rRNA, we isolate the crosslinked species and determine its structure to 3.0 Å resolution. Notably, the 87-mer rRNA adopts an L-shaped conformation characteristic of tRNAs, rather than the conformation it assumes in the ribosome. One Sentence Summary: Cryo-EM structure of Cfr, a radical S-adenosylmethionine methylase that confers antibiotic resistance
- 14 July 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (8) , 2076-2085
Biocatalytic Aerobic Oxidation for Large-Scale Production of trans-3-Hydroxy-l-Proline
- 14 July 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (8) , 2076-2085
Biocatalytic Aerobic Oxidation for Large-Scale Production of trans-3-Hydroxy-l-Proline
- 23 December 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (1) , 92-99
Impurity Control Strategy of TMS-Triol in the Manufacture Development of Islatravir
- 23 December 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (1) , 92-99
Impurity Control Strategy of TMS-Triol in the Manufacture Development of Islatravir
- 14 August 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (9) , 3545-3559
Development of a Biocatalytic Aerobic Oxidation for the Manufacturing Route to Islatravir
- 14 August 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (9) , 3545-3559
Development of a Biocatalytic Aerobic Oxidation for the Manufacturing Route to Islatravir